Focus of the month - Alzheimer's Disease
Novo Nordisk taps Ypsomed to manufacture GLP-1 autoinjectors
Novo Nordisk hikes full-year forecast on GLP-1 drug sales | Reuters
Novo Nordisk promotes new GLP-1 receptor agonist to fight diabetes, obesity < Pharma < Article - KBR
Werking van GLP-1
GLP-1 analogs, new trend in obesity treatment, become even more effective < Pharma < Article - KBR
IJMS | Free Full-Text | Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases
Glucagon-Like Peptide-1 (Glp-1) Analogs Market will generate new growth opportunities 2022-2028 | Novo Nordisk, Eli-Lilly and Company | Medgadget
UK probes Novo's Ozempic, Saxenda over suicidal thoughts
Type 2 Diabetes and the Role of GLP-1 | Diabetes Education for Patients | novoMEDLINK™
The Now Generation & New Generation of GLP-1 RAs: Reshaping the Care of T2DM
Wegovy wows investors, sends ripples throughout GLP-1 developer space | BioWorld
New GLP-1 weight loss drugs are about to ship to more American homes
Diabetes Patients Also Struggle to Access GLP-1 Agonists | MedPage Today
IJMS | Free Full-Text | GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives
Analogue du GLP-1 hebdomadaire | Le Quotidien du Pharmacien
GLP-1: The Reliable Partner | circulatory system | GLP-1 is your reliable partner in treating type 2 diabetes. They work by mimicking the functions of natural incretin hormones -- including stimulating... | By Novo Nordisk | Facebook
Novo Nordisk plans multi-billion Denmark manufacturing expansion
FDA Approves First Oral GLP-1 RA
Recent updates on GLP-1 agonists: Current advancements & challenges - ScienceDirect
CIMB | Free Full-Text | The Role of GLP1-RAs in Direct Modulation of Lipid Metabolism in Hepatic Tissue as Determined Using In Vitro Models of NAFLD
User-unfriendly Pen costs Sanofi lead on new Diabetes Drug Combo
GLP-1 Drugs Drop More Than Just Weight | Penn Mutual Asset Management
Walmart, Coca-Cola Sink As GLP-1 Drugs Raise Alarms About Food Demand
NOVO NORDISK GLP-1 PRESENTATION DESIGN :: Behance
EMA will monitor suicide risk in Novo Nordisk's GLP-1 products
